Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases.
- Author:
Thomas GRUNWALD
1
;
Sebastian ULBERT
Author Information
- Publication Type:Review
- Keywords: DNA vaccines; Gene transfer techniques; Immunologic adjuvants; Infection
- MeSH: Adjuvants, Immunologic; Animals; Antigen Presentation; Communicable Diseases*; DNA*; Electroporation; Gene Transfer Techniques; Humans; Immunity, Humoral; Immunization; Plasmids; Rodentia; Vaccination*; Vaccines, DNA
- From:Clinical and Experimental Vaccine Research 2015;4(1):1-10
- CountryRepublic of Korea
- Language:English
- Abstract: Advantages of DNA vaccination against infectious diseases over more classical immunization methods include the possibilities for rapid manufacture, fast adaptation to newly emerging pathogens and high stability at ambient temperatures. In addition, upon DNA immunization the antigen is produced by the cells of the vaccinated individual, which leads to activation of both cellular and humoral immune responses due to antigen presentation via MHC I and MHC II molecules. However, so far DNA vaccines have shown most efficient immunogenicity mainly in small rodent models, whereas in larger animals including humans there is still the need to improve effectiveness. This is mostly due to inefficient delivery of the DNA plasmid into cells and nuclei. Here, we discuss technologies used to overcome this problem, including physical means such as in vivo electroporation and co-administration of adjuvants. Several of these methods have already entered clinical testing in humans.
